DLL3 and small cell lung carcinoma: An analogous approach targeting DLL3, applying the bispecific T-cell engager (BiTE) AMG 757, is currently underway (NCT03319940).160,205 CAR-T therapies have been tested recently in various solid tumors, and is expected to be investigated further in SCLC.